SecBot SecBot
SECBOTREPLAY Home › Report › FULC

FULC · Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive…

Fulcrum Therapeutics, Inc. · 425 filed Aug 17, 2026 at 08:31 ET

At the news

BULLISHIMPACT 8/10

425 filed Aug 17, 2026 at 08:31 ET

Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Slate in an all-stock reverse merger. Fulcrum is valued at $31.3M and Slate at $350M, with a concurrent $245M PIPE led by Frazier Life Sciences. Pre-merger FULC stockholders will receive a special cash dividend of approximately $270M (subject to adjustment) and will own ~5% of the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The deal is expected to close in Q4 2026.

  • Fulcrum valued at $31.3M, Slate at $350M in all-stock merger
  • $245M concurrent PIPE from Frazier Life Sciences, Forbion, RA Capital, and others
  • Pre-merger FULC stockholders to own ~5% of combined company on a fully-diluted basis
  • FULC stockholders to receive ~$270M special cash dividend (subject to adjustment based on net cash)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access